Jason Harris | Authors


Sitravatinib Plus Nivolumab Induces Durable Responses in Advanced NSCLC After ICIs, Chemotherapy

September 21, 2021

Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Frontline Venetoclax and Obinutuzumab Maintains Delay of Progression in CLL

June 15, 2021

With further follow-up from the phase 3 CLL14 trial, the median progression-free survival was still reached with the fixed-dose regimen of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.